Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma
- 1 April 2014
- journal article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 46 (4) , 358-362
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinomaJournal of Hepatology, 2012
- Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”Journal of Hepatology, 2012
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2012
- Hepatocellular carcinomaThe Lancet, 2012
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Prospective Cohort Study of Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma in 8510 PatientsGastroenterology, 2006
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Meta-Analysis of Randomized Controlled TrialsRadiology, 2002
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002